Compare DexCom, Inc. (DXCM) vs Iris Energy Limited (IREN) Price & Performance

DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.

The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.

IREN trades at $43.67, up 12.73% in the last 24 hours, reflecting strong momentum amid recent AI contract wins. The technical picture is neutral with mixed signals, while fundamentals show robust revenue growth and high gross margins but negative returns on equity and assets. Recent news highlights the company's pivot to AI infrastructure, including a $2.8 billion contract boost and a raised revenue target above $4 billion, driving investor optimism despite recent earnings misses.

The outlook is cautiously optimistic, with significant growth potential from AI cloud expansion but tempered by execution risks and high valuation multiples. Analyst consensus is bullish with a $84.43 price target, though investors should monitor cash flow sustainability and competitive pressures in the rapidly evolving AI infrastructure space.